Refinement of the magnetic resonance diffusion-perfusion mismatch concept for thrombolytic patient selection: Insights from the desmoteplase in acute stroke trials

Stroke

Volumn 43, Issue 9, 2012, Pages 2313-2318

  Warach, Steven ^a   Al Rawi, Yasir ^b   Furlan, Anthony J ^c   Fiebach, Jochen B ^d   Wintermark, Max ^e   Lindstén, Annika ^f   Smyej, Jamal ^f   Bharucha, David B ^g   Pedraza, Salvador ^h   Rowley, Howard A ⁱ  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b Signen Biomedical Consulting FZE   (United Arab Emirates)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF VIRGINIA   (United States)

^f H LUNDBECK A S   (Denmark)

^g FOREST RESEARCH INSTITUTE   (United States)

^h HOSPITAL JOSEP TRUETA   (Spain)

ⁱ UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

acute cerebral infarction; desmoteplase; diffusion weighted imaging; magnetic resonance imaging; mismatch; perfusion; stroke; thrombolysis

Indexed keywords

DESMOTEPLASE; PLACEBO;

ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FIBRINOLYTIC THERAPY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PERFUSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ODDS RATIO; PLASMINOGEN ACTIVATORS; REPERFUSION; SAMPLE SIZE; STROKE; THROMBOLYTIC THERAPY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865607691     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.642348     Document Type: Article

References (31)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
2. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695-1703.
3. Donnan GA, Baron JC, Ma H, Davis SM. Penumbral selection of patients for trials of acute stroke therapy. Lancet Neurol. 2009;8:261-269.
4. Warach S. Thrombolysis in stroke beyond three hours: Targeting patients with diffusion and perfusion MRI. Ann Neurol. 2002;51:11-13.
5. Albers GW. Expanding the window for thrombolytic therapy in acute stroke. The potential role of acute MRI for patient selection. Stroke. 1999;30:2230-2237.
6. Baird AE, Benfield A, Schlaug G, Siewert B, Lövblad KO, Edelman RR, et al. Enlargement of human cerebral ischemic lesion volumes measured by diffusion-weighted magnetic resonance imaging. Ann Neurol. 1997; 41:581-589.
7. Warach S, Pettigrew LC, Dashe JF, Pullicino P, Lefkowitz DM, Sab-ounjian L, et al. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. Ann Neurol. 2000;48:713-722.
8. Beaulieu C, de Crespigny A, Tong DC, Moseley ME, Albers GW, Marks MP. Longitudinal magnetic resonance imaging study of perfusion and diffusion in stroke: evolution of lesion volume and correlation with clinical outcome. Ann Neurol. 1999;46:568-578.
9. Lövblad KO, Baird AE, Schlaug G, Benfield A, Siewert B, Voetsch B, et al. Ischemic lesion volumes in acute stroke by diffusion-weighted magnetic resonance imaging correlate with clinical outcome. Ann Neurol. 1997;42:164-170.
10. Chalela JA, Kang DW, Luby M, Ezzeddine M, Latour LL, Todd JW, et al. Early magnetic resonance imaging findings in patients receiving tissue plasminogen activator predict outcome: Insights into the pathophysiology of acute stroke in the thrombolysis era. Ann Neurol. 2004;55:105-112.
11. Merino JG, Latour LL, Todd JW, Luby M, Schellinger PD, Kang DW, et al. Lesion volume change after treatment with tissue plasminogen activator can discriminate clinical responders from nonresponders. Stroke. 2007;38:2919-2923.
12. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36:66-73.
13. Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. 2006;37:1227-1231.
14. Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2009;8:141-150.
15. Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, Skalabrin E, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol. 2006;60: 508-517.
16. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008;7:299-309.
17. Olivot JM, Mlynash M, Thijs VN, Kemp S, Lansberg MG, Wechsler L, et al. Optimal Tmax threshold for predicting penumbral tissue in acute stroke. Stroke. 2009;40:469-475.
18. Takasawa M, Jones PS, Guadagno JV, Christensen S, Fryer TD, Harding S, et al. How reliable is perfusion MR in acute stroke? Validation and determination of the penumbra threshold against quantitative PET. Stroke. 2008;39:870-877.
19. Røhl L, Ostergaard L, Simonsen CZ, Vestergaard-Poulsen P, Andersen G, et al. Viability thresholds of ischemic penumbra of hyperacute stroke defined by perfusion-weighted MRI and apparent diffusion coefficient. Stroke. 2001;32:1140-1146.
20. Kane I, Carpenter T, Chappell F, Rivers C, Armitage P, Sandercock P, et al. Comparison of 10 different magnetic resonance perfusion imaging processing methods in acute ischemic stroke: effect on lesion size, proportion of patients with diffusion/perfusion mismatch, clinical scores, and radiologic outcomes. Stroke. 2007;38:3158-3164.
21. Kakuda W, Lansberg MG, Thijs VN, Kemp SM, Bammer R, Wechsler LR, et al. Optimal definition for PWI/DWI mismatch in acute ischemic stroke patients. J Cereb Blood Flow Metab. 2008;28:887-891.
22. Luby M, Bykowski JL, Schellinger PD, Merino JG, Warach S. Intra-and interrater reliability of ischemic lesion volume measurements on diffusion-weighted, mean transit time and fluid-attenuated inversion recovery MRI. Stroke. 2006;37:2951-2956.
23. Luby M, Ku KD, Latour LL, Merino JG, Hsia AW, Lynch JK, Warach S. Visual perfusion-diffusion mismatch is equivalent to quantitative mismatch. Stroke. 2011;42:1010-1014.
24. Christensen S, Mouridsen K, Wu O, Hjort N, Karstoft H, Thomalla G, et al. Comparison of 10 perfusion MRI parameters in 97 sub-6-hour stroke patients using voxel-based receiver operating characteristics analysis. Stroke. 2009;40:2055-2061.
25. Schellinger PD, Latour LL, Wu CS, Chalela JA, Warach S. The association between neurological deficit in acute ischemic stroke and mean transit time: comparison of four different perfusion MRI algorithms. Neuroradiology. 2006;48:69-77.
26. Grandin CB, Duprez TP, Smith AM, Oppenheim C, Peeters A, Robert AR, et al. Which MR-derived perfusion parameters are the best predictors of infarct growth in hyperacute stroke? Comparative study between relative and quantitative measurements. Radiology. 2002;223:361-370.
27. Kudo K, Sasaki M, Østergaard L, Christensen S, Uwano I, Suzuki M, et al. Susceptibility of Tmax to tracer delay on perfusion analysis: quantitative evaluation of various deconvolution algorithms using digital phantoms. J Cereb Blood Flow Metab. 2011;31:908-912.
28. Lansberg MG, Lee J, Christensen S, Straka M, De Silva DA, Mlynash M, et al. RAPID automated patient selection for reperfusion therapy: a pooled analysis of the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) and the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) Study. Stroke. 2011;42: 1608-1614.
29. Wintermark M, Albers GW, Alexandrov AV, Alger JR, Bammer R, Baron JC, et al. Acute stroke imaging research roadmap. Stroke. 2008; 39:1621-1628.
30. Fiebach JB, Al-Rawi Y, Wintermark M, Furlan AJ, Rowley HA, Lindsten A, et al. Vascular occlusion enables selecting acute ischemic stroke patients for treatment with desmoteplase. Stroke. 2012;43:1561-1566.
31. Parsons MW, Christensen S, McElduff P, Levi CR, Butcher KS, De Silva DA, et al. Pretreatment diffusion-and perfusion-MR lesion volumes have a crucial influence on clinical response to stroke thrombolysis. J Cereb Blood Flow Metab. 2010;30:1214-1225.